Review article: biological agents in the treatment of Crohn's disease (Q34799343)

4 August 2017

1 reference

title

Review article: biological agents in the treatment of Crohn's disease (English)

1 reference

4 August 2017

0 references

Caprilli R

1

1 reference

4 August 2017

Viscido A

series ordinal

2

1 reference

4 August 2017

Guagnozzi D

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Alimentary Pharmacology & Therapeutics

4 August 2017

published in

1 reference

4 August 2017

volume

16

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

1579-1590

1 reference

Inflammatory bowel disease: etiology and pathogenesis

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

The key role of macrophages in the immunopathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Pathways for self-tolerance and the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Taming TNF: strategies to restrain this proinflammatory cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Migration of T cells in vivo: molecular mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Adhesion molecules in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Activation of nuclear factor kappa B inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

NF-kappaB: a key role in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

The regulation of AP-1 activity by mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Positive versus negative signaling by lymphocyte antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01319.X

10.1046/J.1365-2036.2002.01319.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference